腸がん治療薬の世界市場レポート 2025年

腸がん治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.5％で211億5,000万米ドルに成長します。予測期間の成長は、免疫療法の進歩、精密医療と個別化療法、新たな標的療法、人工知能（AI）の統合、患者中心のアプローチに起因すると考えられます。予測期間の主な動向には、リキッドバイオプシー技術、精密医療とバイオマーカー調査、併用療法、患者中心のケアと支持療法、低侵襲手術技術の採用などがあります。

遺伝性大腸がん症候群の有病率の増加が予想され、腸がん治療薬市場の成長を牽引するとみられます。これらの症候群は、大腸がんのリスクを高める遺伝的条件であり、大腸がん開発の可能性を著しく増幅させる特定の遺伝子変異に関連する情報を提供することにより、腸がん治療において極めて重要な役割を果たしています。2023年7月の世界保健機関（WHO）の予測によると、遺伝性大腸がんの有病率は2040年までに大幅に増加し、毎年320万人が新たに発症し、160万人が死亡すると推定されています。これは、現在と比較して新規症例が63％増加し、死亡者数が73％急増することを意味します。その結果、遺伝性大腸がん症候群の有病率の上昇が腸がん治療薬市場の主要な促進要因となっています。

個別化医療に対する需要の高まりは、腸がん治療薬市場の成長を促進すると予測されています。個別化医療とは、医療上の意思決定や薬物療法を患者固有の特徴に合わせて調整することで、腸がん治療薬における治療効果を高め、副作用を最小限に抑えるものです。2022年、米食品医薬品局（FDA）の医薬品評価研究センター（CDER）は37の新規分子化合物（NME）を承認し、そのうち約34％にあたる12が個別化医療連合（PMC）によって個別化医薬品に分類されました。このことは、個別化医療に対する需要の高まりを裏付けており、腸がん治療薬市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界腸がん治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の腸がん治療薬市場：成長率分析
• 世界の腸がん治療薬市場の実績：規模と成長, 2019-2024
• 世界の腸がん治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界腸がん治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の腸がん治療薬市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫療法
• 化学療法
• その他の治療法
• 世界の腸がん治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界の腸がん治療薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門センター
• その他の用途
• 世界の腸がん治療薬市場、免疫療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• チェックポイント阻害剤
• CAR T細胞療法
• がんワクチン
• 世界の腸がん治療薬市場化学療法の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 補助化学療法
• 術前化学療法
• 緩和化学療法
• 世界の腸がん治療薬市場、その他の治療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標的療法
• 放射線治療
• 手術
• ホルモン療法

第7章 地域別・国別分析

• 世界の腸がん治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の腸がん治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 腸がん治療薬市場：競合情勢
• 腸がん治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• Abbott Laboratories
• GSK plc.
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Merck KGaA
• Mylan N.V.
• Astellas Pharma Inc.
• Daiichi Sankyo Company Limited
• Eisai Co. Ltd.
• Boehringer Ingelheim International GmbH
• Sun Pharmaceutical Industries Ltd.
• Ipsen Pharma

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 腸がん治療薬市場2029：新たな機会を提供する国
• 腸がん治療薬市場2029：新たな機会を提供するセグメント
• 腸がん治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Intestine cancer therapeutics encompass the diverse treatment options available for addressing small intestine and colorectal cancer that impact the digestive system. These treatments aim to either eliminate or manage cancerous cells with the overarching goal of improving patient outcomes. The specific treatment plan is determined by factors such as the cancer stage, the patient's overall health, and other individual considerations.

The primary types of treatments for intestine cancer therapeutics include immunotherapy, chemotherapy, and other modalities. Immunotherapy, a form of cancer treatment, harnesses the body's immune system to combat cancer cells. These therapeutic options are distributed through various channels such as hospital pharmacies, online pharmacies, and retail pharmacies. They are commonly utilized by institutions such as hospitals, homecare facilities, specialty centers, and others.

The intestine cancer therapeutics market research report is one of a series of new reports from The Business Research Company that provides intestine cancer therapeutics market statistics, including intestine cancer therapeutics industry global market size, regional shares, competitors with an intestine cancer therapeutics market share, detailed intestine cancer therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the intestine cancer therapeutics industry. This intestine cancer therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The intestine cancer therapeutics market size has grown strongly in recent years. It will grow from $14 billion in 2024 to $15.26 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to advancements in medical research, increased cancer incidence, chemotherapy and radiation therapies, screening and early detection initiatives, genetic and biomarker discoveries.

The intestine cancer therapeutics market size is expected to see strong growth in the next few years. It will grow to $21.15 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to immunotherapy advancements, precision medicine and personalized therapies, emerging targeted therapies, integration of artificial intelligence (AI), patient-centric approaches. Major trends in the forecast period include liquid biopsy technologies, precision medicine and biomarker research, combination therapies, patient-centric care and supportive therapies, adoption of minimally invasive surgical techniques.

The anticipated increase in the prevalence of hereditary colorectal cancer syndromes is poised to drive the growth of the intestine cancer therapeutics market. These syndromes, genetic conditions that elevate the risk of colorectal cancer, play a pivotal role in intestinal cancer therapeutics by providing information linked to specific genetic mutations significantly amplifying the likelihood of colorectal cancer development. As per the World Health Organization's projections in July 2023, the prevalence of hereditary colorectal cancer is expected to witness a substantial rise by 2040, with an estimated 3.2 million new cases and 1.6 million deaths annually. This represents a 63% increase in new cases and a 73% surge in fatalities compared to current rates. Consequently, the escalating prevalence of hereditary colorectal cancer syndromes is a key driver of the intestine cancer therapeutics market.

The growing demand for personalized medicine is anticipated to propel the growth of the intestine cancer therapeutics market. Personalized medicine, tailoring medical decisions and drug therapies to a patient's unique characteristics, enhances treatment effectiveness and minimizes side effects in intestine cancer therapeutics. In 2022, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34%, or 12 of them, classified as personalized medicines by the Personalized Medicine Coalition (PMC). This underscores the rising demand for personalized medicine, driving the growth of the intestine cancer therapeutics market.

Major companies operating in the intestine cancer therapeutics market are actively developing innovative products, such as Lonsurf, and securing approvals to broaden their customer bases, increase sales, and boost revenue. Lonsurf, a combination of trifluridine and tipiracil, received approval from the US Food and Drug Administration in August 2023 for treating adult patients with metastatic colorectal cancer. Taiho Oncology Inc., the US-based pharmaceutical company behind Lonsurf, aims to provide patients with metastatic colorectal cancer and other eligible cancers a new treatment option to potentially enhance outcomes and improve quality of life.

In September 2022, CytoReason Ltd, an Israel-based biotechnology company, joined forces with Pfizer Inc. for AI-driven drug discovery and development. Pfizer's drug research activities will incorporate CytoReason's AI technologies under this collaboration, which may be valued up to $110 million over the next five years. The agreement involves Pfizer contributing $20 million in stock, offering options to license CytoReason's platform and disease models, and providing additional project support. Pfizer Inc., a US-based pharmaceutical company, contributes to the advancements in intestine cancer therapeutics through this collaboration.

Major companies operating in the intestine cancer therapeutics market report are Pfizer Inc., Johnson & Johnson Private Limited, Roche Holding AG, AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GSK plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck KGaA, Mylan N.V., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Ipsen Pharma, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Cipla Inc., Aurobindo Pharma Limited, Lupin Limited

Asia-Pacific was the largest region in the intestine cancer therapeutics market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the intestine cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the intestine cancer therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The intestine cancer therapeutics market includes revenues earned by entities by provide services such as colonoscopies and fecal occult blood tests, clinical trials, supportive care, genetic testing and counseling, and psychological support. The market value includes the value of related goods sold by the service provider or included within the service offering. The intestine cancer therapeutics market also includes sales of Alymsys, Avastin (bevacizumab), bevacizumab, Camptosar (irinotecan hydrochloride), capecitabine, cetuximab, angiogenesis inhibitors, multikinase inhibitors, epigenetic agents, and supportive care products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Intestine Cancer Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on intestine cancer therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for intestine cancer therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The intestine cancer therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Immunotherapy; Chemotherapy; Other Treatments
• 2) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 3) By Application: Hospitals; Homecare; Specialty Centers; Other Applications
• Subsegments:
• 1) By Immunotherapy: Checkpoint Inhibitors; CAR T-Cell Therapy; Cancer Vaccines
• 2) By Chemotherapy: Adjuvant Chemotherapy; Neoadjuvant Chemotherapy; Palliative Chemotherapy
• 3) By Other Treatments: Targeted Therapy; Radiation Therapy; Surgery; Hormone Therapy
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Private Limited; Roche Holding AG; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Intestine Cancer Therapeutics Market Characteristics

3. Intestine Cancer Therapeutics Market Trends And Strategies

4. Intestine Cancer Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Intestine Cancer Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Intestine Cancer Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Intestine Cancer Therapeutics Market Growth Rate Analysis
• 5.4. Global Intestine Cancer Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Intestine Cancer Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Intestine Cancer Therapeutics Total Addressable Market (TAM)

6. Intestine Cancer Therapeutics Market Segmentation

• 6.1. Global Intestine Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunotherapy
• Chemotherapy
• Other Treatments
• 6.2. Global Intestine Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• 6.3. Global Intestine Cancer Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Centers
• Other Applications
• 6.4. Global Intestine Cancer Therapeutics Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Checkpoint Inhibitors
• CAR T-Cell Therapy
• Cancer Vaccines
• 6.5. Global Intestine Cancer Therapeutics Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adjuvant Chemotherapy
• Neoadjuvant Chemotherapy
• Palliative Chemotherapy
• 6.6. Global Intestine Cancer Therapeutics Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeted Therapy
• Radiation Therapy
• Surgery
• Hormone Therapy

7. Intestine Cancer Therapeutics Market Regional And Country Analysis

• 7.1. Global Intestine Cancer Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Intestine Cancer Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Intestine Cancer Therapeutics Market

• 8.1. Asia-Pacific Intestine Cancer Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Intestine Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Intestine Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Intestine Cancer Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Intestine Cancer Therapeutics Market

• 9.1. China Intestine Cancer Therapeutics Market Overview
• 9.2. China Intestine Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Intestine Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Intestine Cancer Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Intestine Cancer Therapeutics Market

• 10.1. India Intestine Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Intestine Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Intestine Cancer Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Intestine Cancer Therapeutics Market

• 11.1. Japan Intestine Cancer Therapeutics Market Overview
• 11.2. Japan Intestine Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Intestine Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Intestine Cancer Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Intestine Cancer Therapeutics Market

• 12.1. Australia Intestine Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Intestine Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Intestine Cancer Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Intestine Cancer Therapeutics Market

• 13.1. Indonesia Intestine Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Intestine Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Intestine Cancer Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Intestine Cancer Therapeutics Market

• 14.1. South Korea Intestine Cancer Therapeutics Market Overview
• 14.2. South Korea Intestine Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Intestine Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Intestine Cancer Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Intestine Cancer Therapeutics Market

• 15.1. Western Europe Intestine Cancer Therapeutics Market Overview
• 15.2. Western Europe Intestine Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Intestine Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Intestine Cancer Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Intestine Cancer Therapeutics Market

• 16.1. UK Intestine Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Intestine Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Intestine Cancer Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Intestine Cancer Therapeutics Market

• 17.1. Germany Intestine Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Intestine Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Intestine Cancer Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Intestine Cancer Therapeutics Market

• 18.1. France Intestine Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Intestine Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Intestine Cancer Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Intestine Cancer Therapeutics Market

• 19.1. Italy Intestine Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Intestine Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Intestine Cancer Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Intestine Cancer Therapeutics Market

• 20.1. Spain Intestine Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Intestine Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Intestine Cancer Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Intestine Cancer Therapeutics Market

• 21.1. Eastern Europe Intestine Cancer Therapeutics Market Overview
• 21.2. Eastern Europe Intestine Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Intestine Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Intestine Cancer Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Intestine Cancer Therapeutics Market

• 22.1. Russia Intestine Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Intestine Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Intestine Cancer Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Intestine Cancer Therapeutics Market

• 23.1. North America Intestine Cancer Therapeutics Market Overview
• 23.2. North America Intestine Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Intestine Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Intestine Cancer Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Intestine Cancer Therapeutics Market

• 24.1. USA Intestine Cancer Therapeutics Market Overview
• 24.2. USA Intestine Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Intestine Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Intestine Cancer Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Intestine Cancer Therapeutics Market

• 25.1. Canada Intestine Cancer Therapeutics Market Overview
• 25.2. Canada Intestine Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Intestine Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Intestine Cancer Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Intestine Cancer Therapeutics Market

• 26.1. South America Intestine Cancer Therapeutics Market Overview
• 26.2. South America Intestine Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Intestine Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Intestine Cancer Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Intestine Cancer Therapeutics Market

• 27.1. Brazil Intestine Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Intestine Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Intestine Cancer Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Intestine Cancer Therapeutics Market

• 28.1. Middle East Intestine Cancer Therapeutics Market Overview
• 28.2. Middle East Intestine Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Intestine Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Intestine Cancer Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Intestine Cancer Therapeutics Market

• 29.1. Africa Intestine Cancer Therapeutics Market Overview
• 29.2. Africa Intestine Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Intestine Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Intestine Cancer Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Intestine Cancer Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Intestine Cancer Therapeutics Market Competitive Landscape
• 30.2. Intestine Cancer Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Intestine Cancer Therapeutics Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi S.A.
• 31.3. Bristol-Myers Squibb Company
• 31.4. Abbott Laboratories
• 31.5. GSK plc.
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Eli Lilly and Company
• 31.8. Merck KGaA
• 31.9. Mylan N.V.
• 31.10. Astellas Pharma Inc.
• 31.11. Daiichi Sankyo Company Limited
• 31.12. Eisai Co. Ltd.
• 31.13. Boehringer Ingelheim International GmbH
• 31.14. Sun Pharmaceutical Industries Ltd.
• 31.15. Ipsen Pharma

32. Global Intestine Cancer Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Intestine Cancer Therapeutics Market

34. Recent Developments In The Intestine Cancer Therapeutics Market

35. Intestine Cancer Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Intestine Cancer Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Intestine Cancer Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Intestine Cancer Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer